Provided by Tiger Fintech (Singapore) Pte. Ltd.

iBio

0.9265
-0.0618-6.25%
Post-market: 0.9000-0.0265-2.86%19:56 EDT
Volume:460.37K
Turnover:420.39K
Market Cap:15.31M
PE:-0.40
High:1.00
Open:1.00
Low:0.8754
Close:0.9883
Loading ...

Vaccine Stocks Surge with Moderna up 11%

Tiger Newspress
·
20 May

Trump Says He Will Cut Drug Prices by 59%

Reuters
·
12 May

iBio Is Maintained at Buy by Chardan Capital

Dow Jones
·
05 May

Ibio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy With Glp-1S in Preclinical Model

THOMSON REUTERS
·
05 May

iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

GlobeNewswire
·
05 May

iBio, Inc. Reports Strong Q3 2025 Progress

TIPRANKS
·
05 May

BRIEF-iBio Reports Fiscal Third Quarter 2025 Financial Results

Reuters
·
02 May

iBio Q3 EPS $(0.49) Misses $(0.34) Estimate

Benzinga
·
02 May

Ibio Inc: Qtrly EPS From Cont Ops -$0.49

THOMSON REUTERS
·
02 May

Press Release: iBio Reports Fiscal Third Quarter 2025 Financial Results

Dow Jones
·
02 May

BRIEF-Ibio Inc Enters Exclusive License Agreement With AstralBio

Reuters
·
23 Apr

iBio Enters Licensing Agreement for Obesity Treatment

TIPRANKS
·
23 Apr

Ibio - Licensing Agreement With Astralbio for Preclinical First-in-Class Antibody Targeting Activin E

THOMSON REUTERS
·
23 Apr

Ibio Inc - Enters Exclusive License Agreement With Astralbio

THOMSON REUTERS
·
23 Apr

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

GlobeNewswire
·
22 Apr

Pharma Stocks Sink After Trump Says "Major" Tariffs Are Coming

Tiger Newspress
·
09 Apr

BRIEF-Ibio Inc - On Track For Regulatory Submission For Ibio-600 In Q1 2026

Reuters
·
07 Apr

iBio Reveals Promising Study Results for IBIO-600

TIPRANKS
·
07 Apr

Ibio Inc - on Track for Regulatory Submission for Ibio-600 in Q1 2026

THOMSON REUTERS
·
07 Apr

Ibio Announces Ibio-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim in Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

THOMSON REUTERS
·
07 Apr